Search results for " peripheral arterial disease"

showing 10 items of 10 documents

Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.

2013

AdultMaleRegistrieRiskMiddle AgedPeripheral Arterial Diseaseatrial fibrillation; cardiovascular disease; peripheral vascular disease; Adult; Aged; Atrial Fibrillation; Female; Humans; Internal Medicine; Italy; Male; Middle Aged; Peripheral Arterial Disease; Prevalence; Registries; Risk; Societies Medical; Ankle Brachial Index; Cardiology and Cardiovascular MedicineItalycardiovascular diseaseperipheral vascular diseaseMedicalAtrial FibrillationInternal MedicinePrevalenceHumansFemaleAnkle Brachial IndexRegistriesSocietiesCardiology and Cardiovascular MedicineSocieties MedicalAgedHuman
researchProduct

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the…

2004

Aims Patients with diabetes are at excessive risk of mortality and cardiovascular morbidity. Previous studies suggest that aspirin may be less effective in diabetic patients. In this multi-centre, randomized, double blind trial picotamide, a dual inhibitor of thromboxane A2 synthase and receptor, was compared with aspirin for the prevention of mortality and major cardiovascular events in diabetics with peripheral arterial disease (PAD). Methods and results A total of 1209 adults aged 40–75 years with type 2 diabetes and PAD were randomized to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 months. The cumulative incidence of the 2 years overall mortality was significantly lowe…

AdultMalemedicine.medical_specialtyPhthalic AcidsType 2 diabetesDiabeteGastroenterologyThromboxane A2Double-Blind MethodRisk FactorsInternal medicineDiabetes mellitusPeripheral arterial diseasemedicineRisk of mortalityHumansPicotamideCumulative incidenceGeneral NursingAgedPeripheral Vascular DiseasesAspirinAspirinbiologybusiness.industryAntiplatelet therapyantiplatelet therapy; aspirin; diabetes; peripheral arterial disease; picotamide; thromboxane synthase inhibitorsMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryThromboxane synthase inhibitors Indexed keywordsRelative riskbiology.proteinFemaleThromboxane-A synthasePicotamideCardiology and Cardiovascular MedicinebusinessDiabetic AngiopathiesPlatelet Aggregation InhibitorsFollow-Up Studiesmedicine.drugEuropean Heart Journal
researchProduct

Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender

2019

International audience; BACKGROUND AND AIM:Heterozygous familial hypercholesterolemia (HeFH) is a genetic disease characterized by a heterogeneous phenotype. The assessment of cardiovascular (CV) risk is challenging for HeFH. Cholesterol burden (CB) allows to estimate the lifelong exposure to high levels of cholesterol. The aim of this study was to analyze the distribution of subclinical atherosclerosis and the relationship between atherosclerosis and the CB in a sample of HeFH patients, focusing on sex-related differences.METHODS AND RESULTS:154 asymptomatic HeFH subjects underwent coronary-artery-calcium score (CACs) and Doppler ultrasound of carotid and femoral arteries. Yearly lipid pro…

Carotid Artery DiseasesMaleCarotid atherosclerosisPeripheral arterial atherosclerosisTime Factors[SDV]Life Sciences [q-bio]Endocrinology Diabetes and MetabolismMedicine (miscellaneous)Coronary Artery DiseaseDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologySeverity of Illness Indexchemistry.chemical_compound0302 clinical medicineRisk FactorsAtherosclerosis; Calcium score; Cardiovascular disease; Cardiovascular risk; Cholesterol burden; Coronary artery calcium; Familial hypercholesterolemia; Peripheral arterial atherosclerosis; Adult; Aged; Asymptomatic Diseases; Biomarkers; Carotid Artery Diseases; Cholesterol; Coronary Artery Disease; Cross-Sectional Studies; Female; Femoral Artery; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Paris; Peripheral Arterial Disease; Phenotype; Prevalence; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Sex Factors; Time Factors; Young AdultPrevalenceMedicineNutrition and Dietetics[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMiddle AgedPrognosisCardiovascular diseaseCalcium score3. Good healthFemoral ArteryCholesterol burdenCholesterolPhenotypeAtherosclerosiCardiologyPopulation studyFemalemedicine.symptomCardiology and Cardiovascular MedicineAdultParismedicine.medical_specialtyFamilial hypercholesterolemia030209 endocrinology & metabolismRisk AssessmentAsymptomaticCoronary artery calciumHigh cholesterolHyperlipoproteinemia Type IIPeripheral Arterial DiseaseYoung Adult03 medical and health sciencesSex Factors[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineHumansGenetic Predisposition to DiseaseAgedbusiness.industryCholesterolAtherosclerosismedicine.diseaseCardiovascular riskCross-Sectional StudieschemistrySubclinical atherosclerosisAsymptomatic DiseasesbusinessBiomarkers
researchProduct

Consensus Document on Intermittent Claudication from the Central European Vascular Forum (C.E.V.F.)-3rd revision (2013) with the sharing of the Medit…

2014

This paper is the review of the Consensus Document on Intermittent Claudication of the Central European Vascular Forum (CEVF), published in 2008, and and shared with the North Africa and Middle East Chapter of International Union of Angiology and the Mediterranean League of Angiology and Vascular Surgery. The Document presents suggestions for general practitioners and vascular specialists for more precise and appropriate management of PAD, particularly of intermittent claudication, and underlines the investigations that should be required by GPs and what the GP should expect from the vascular specialist (angiologist, vascular surgeon). The idea of the Faculty is to produce a short document,…

ConsensusCritical IllnessGeneral Practiceintermittent claudicatioCardiovascular AgentsIntermittent ClaudicationSettore MED/11 - Malattie Dell'Apparato CardiovascolareSeverity of Illness IndexPeripheral Arterial DiseaseTreatment OutcomeIschemiaRisk FactorsAsymptomatic DiseasesHumansconsensus; intermittent claudicatio; peripheral arterial diseaseReferral and ConsultationRisk Reduction BehaviorVascular Surgical ProceduresIntermittent claudication peripheral arterial disease disease managementInternational angiology : a journal of the International Union of Angiology
researchProduct

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct

Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation

2015

Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 yea…

RegistrieMaleCross-sectional studyMyocardial InfarctionLongitudinal StudieLeft ventricular hypertrophyCohort Studiesnon-valvular atrial fibrillationAtrial Fibrillation80 and overPrevalenceechocardiographyMyocardial infarctionLongitudinal StudiesProspective StudiesRegistriesProspective cohort studyUltrasonographyAged 80 and overeducation.field_of_studyMedicine (all)Atrial fibrillationDiabetes MellituMiddle AgedLeft Ventricularleft ventricular hypertrophyItalyHypertensionCardiologyAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular Medicine; Medicine (all)Hypertrophy Left VentricularFemaleCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyLogistic ModelPopulationConcentric hypertrophySocio-culturalenon-valvular atrial fibrillation left ventricular hypertrophy echocardiography cardiovascular diseasesPeripheral Arterial DiseaseAge DistributionInternal medicinemedicineDiabetes MellitusHumansAnkle Brachial Indexcardiovascular diseaseseducationAgedCross-Sectional Studiebusiness.industryAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular MedicineOdds ratioHypertrophymedicine.diseasecardiovascular diseasesProspective StudieCross-Sectional StudiesLogistic ModelsCohort StudiebusinessAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries
researchProduct

Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients

2018

Angioplasty with drug-coated balloon (DCB) is an emerging and reliable method for the treatment of femoro-popliteal lesions. We report our experience with the Stellarex™ DCB in the first 50 patients. Methods - From July 2015 to November 2017, 50 patients (41 M, 9F), medium age (64 ± 7.4 year) were subject to 33 angioplasties (PTAs) for femoro-popliteal lesions with a paclitaxel-coated balloon (Stellarex™). Based upon clinical data sixteen patients had severe claudication (56% - Rutherford class 3); ten patients suffered from ischemic rest pain (34% - Rutherford class 4); and five presented minor tissue loss (10% - Rutherford class 5). 42% of patients showed femoro-popliteal lesion TASC-II B…

endovascular treatmentdrug-coated balloon; endovascular treatment; peripheral arterial disease; superficial femoral arteryperipheral arterial diseasedrug-coated balloonArticlessuperficial femoral arterySettore MED/22 - Chirurgia VascolareTranslational Medicine @ UniSa
researchProduct

Composite femoro-tibial bypass as alternative solution in complicated revascolarization: Case report

2021

Introduction Peripheral Arterial Disease (PAD) in diabetic patients is a significant cause of Morbility. Long arterial occlusion in patient previously treated can require unusual and complex solution. Herein we report a case of complicated bypass in diabetic patient with history of bypass for bilateral popliteal aneurysm. Presentation of case A 51-year-old male, smoker, with hypertension and diabetes mellitus was referred to our hospital for rest pain in left limb and peripheral cyanosis. Ultrasound doppler (US) showed an occlusion after common femoral artery with patency of Anterior-tibial artery (ATA) two centimeters after the origin. The unavailability of adequate autologous conduit nece…

medicine.medical_specialtyATA anterior-tibial arterymedicine.medical_treatmentDFA deep femoral arteryCase ReportFemoral arterySettore MED/22 - Chirurgia VascolareCLI critical limb ischemiaPopliteal aneurysmPTA posterior tibial artery03 medical and health sciences0302 clinical medicinePAD peripheral arterial diseasemedicine.arteryAngioplastySFA superficial femoral arteryOcclusionmedicineCFA common femoral arteryVeinUS ultrasound dopplerbusiness.industryCritical limb ischemiaCritical limb ischemiaComposite distal bypassArterial occlusionSurgerymedicine.anatomical_structure030220 oncology & carcinogenesisRedo perpheral surgery030211 gastroenterology & hepatologySurgerymedicine.symptombusinessArteryInternational Journal of Surgery Case Reports
researchProduct

Metabolic syndrome and peripheral arterial disease.

2014

medicine.medical_specialtyArterial diseasebusiness.industryInternal medicinemedicineCardiologyGeneral MedicineMetabolic syndromebusinessmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMetabolic syndrome peripheral arterial diseasePeripheralRevista clinica espanola
researchProduct

The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis

2008

Small, dense low density lipoproteins (LDL) are associated with increased risk for cardiovascular disease and seem to be an important predictor of cardiovascular events and progression of coronary artery disease. In addition, the predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III). Less data is available on the role of LDL size in the prevention of vascular diseases, including peripheral arterial disease, carotid artery disease and abdominal aortic aneurysm. The NCEP-ATP III stated that clinical non-coronary atherosclerosis carries a risk for coronary heart disease …

medicine.medical_specialtyEndocrinologybusiness.industryEpidemiologyInternal medicineLow densitymedicineSmall dense LDL coronary heart disease atherosclerosis prevention peripheral arterial disease carotid artery disease abdominal aortic aneurysmbusinessCardiology and Cardiovascular MedicineVascular Disease Prevention
researchProduct